Oyster Point Pharma Drug Patent Portfolio
Oyster Point Pharma owns 1 orange book drug protected by 10 US patents Given below is the list of Oyster Point Pharma's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10456396 | Dry eye treatments | 19 Oct, 2035 | Active |
| US11224598 | Methods of increasing lacrimal proteins | 19 Oct, 2035 | Active |
| US11903941 | Compositions and use of varenicline for treating dry eye | 19 Oct, 2035 | Active |
| US11903942 | Compositions and use of varenicline for treating dry eye | 19 Oct, 2035 | Active |
| US11903943 | Compositions and use of varenicline for treating dry eye | 19 Oct, 2035 | Active |
| US11911380 | Compositions and use of varenicline for treating dry eye | 19 Oct, 2035 | Active |
| US9504644 | Methods of increasing tear production | 19 Oct, 2035 | Active |
| US9504645 | Pharmaceutical formulations for treating ocular conditions | 19 Oct, 2035 | Active |
| US9532944 | Methods of improving ocular discomfort | 19 Oct, 2035 | Active |
| US9597284 | Dry eye treatments | 19 Oct, 2035 | Active |
Latest Legal Activities on Oyster Point Pharma's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Oyster Point Pharma.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 25 Jun, 2024 | US9532944 |
| Patent eCofC Notification | 04 Jun, 2024 | US11903942 |
| Recordation of Patent eCertificate of Correction | 04 Jun, 2024 | US11903942 |
| Mail Patent eCofC Notification | 04 Jun, 2024 | US11903942 |
|
Email Notification
Critical
| 04 Jun, 2024 | US11903942 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 21 May, 2024 | US9504645 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 21 May, 2024 | US9504644 |
| Post Issue Communication - Certificate of Correction | 15 May, 2024 | US11903942 |
| Recordation of Patent eGrant | 27 Feb, 2024 | US11911380 |
|
Recordation of Patent Grant Mailed
Critical
| 27 Feb, 2024 | US11911380 |
| Mail Patent eGrant Notification | 27 Feb, 2024 | US11911380 |
|
Email Notification
Critical
| 27 Feb, 2024 | US11911380 |
| Patent eGrant Notification | 27 Feb, 2024 | US11911380 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 27 Feb, 2024 | US11911380 |
| Recordation of Patent eGrant | 20 Feb, 2024 | US11903942 |
Oyster Point Pharma Drug Patents' Oppositions Filed in EPO
Oyster Point Pharma drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Sep 09, 2021, by Beck Greener Llp. This opposition was filed on patent number EP15852340A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP15852340A | Sep, 2021 | Beck Greener LLP | Granted and Under Opposition |
Oyster Point Pharma's Family Patents
Oyster Point Pharma Drug List
Given below is the complete list of Oyster Point Pharma's drugs and the patents protecting them.
1. Tyrvaya
Tyrvaya is protected by 10 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10456396 | Dry eye treatments |
19 Oct, 2035
(10 years from now)
| Active |
| US11224598 | Methods of increasing lacrimal proteins |
19 Oct, 2035
(10 years from now)
| Active |
| US11903941 | Compositions and use of varenicline for treating dry eye |
19 Oct, 2035
(10 years from now)
| Active |
| US11903942 | Compositions and use of varenicline for treating dry eye |
19 Oct, 2035
(10 years from now)
| Active |
| US11903943 | Compositions and use of varenicline for treating dry eye |
19 Oct, 2035
(10 years from now)
| Active |
| US11911380 | Compositions and use of varenicline for treating dry eye |
19 Oct, 2035
(10 years from now)
| Active |
| US9504644 | Methods of increasing tear production |
19 Oct, 2035
(10 years from now)
| Active |
| US9504645 | Pharmaceutical formulations for treating ocular conditions |
19 Oct, 2035
(10 years from now)
| Active |
| US9532944 | Methods of improving ocular discomfort |
19 Oct, 2035
(10 years from now)
| Active |
| US9597284 | Dry eye treatments |
19 Oct, 2035
(10 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tyrvaya's drug page